Drug news
CHMP recommends Revlimid for treatment of Myelodysplastic Syndromes
The Committee for Medicinal Products for Human Use (CHMP) has recommended Revlimid (lenalidomide)from Celgene for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk Myelodysplastic Syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.